

ASX & MEDIA RELEASE

7 DECEMBER 2012



CHANGE OF DIRECTORS AT NOVOGEN LIMITED

Novogen Limited today announced changes to its Board of Directors with the appointment of Professor Graham E Kelly and Dr Andrew Heaton and the resignation of Mr William D. Rueckert and Mr Peter R. White.

Professor Kelly is the founder and previous CEO and Chairman of Novogen Ltd and Marshall Edwards Inc. Both companies are built on the concept of benzopyran drug technology that emanated from his 25 years in cancer research in the Department of Surgery, The University of Sydney, and the German Central Cancer Research Institute, Heidelberg, Germany and for which he held all relevant patents. Professor Kelly personally oversaw the design and implementation of thirty-three Phase I and II clinical trials, and a multi-national Phase III trial in conjunction with the US FDA.

Dr Heaton has extensive drug discovery background. Dr Heaton studied the complex interactions of signaling molecules associated with the mass spawning phenomena on the Great Barrier Reef. Following completion of his Ph.D studies he completed post-doctoral research discovering molecules with unique biological activity from marine environment. The theme of discovery of biologically active natural products was continued in his tenured academic position investigating a variety of traditional bush medicines. Dr Heaton first joined Novogen in 1998 as General Manager of the drug discovery program; progressing 4 compounds to clinical trials. Dr Heaton was responsible for the design and execution of Novogen drug discovery platform that gave rise to the lead compounds: ME-128, ME 196, ME-143 and ME-344, for which he is the principle inventor on a series global patents. Dr Heaton was instrumental in setting up Triaxial Pharmaceuticals and developing their novel technology platform. Dr Heaton has extensive global experience in translating drug discovery strategies into NCE's in global clinical trials.

Mr Rueckert has served as a director of the company since March, 2009 and Chairman since October, 2010. The Board regrets but respects Mr Rueckert and Mr White's decision to retire from the Board and expressed their appreciation for all their hard work and dedication both have given the company during their term.

Issued for	:	NOVOGEN LIMITED
Listings	:	ASX (CODE NRT), NASDAQ (CODE NVGN)
FOR FURTHER INFORMATION	:	STEVEN COFFEY, SECRETARY 02 94165355